Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

GE9:GR

77.600 EUR 0.130 0.17%

As of 13:35:31 ET on 05/25/2015.

Snapshot for Genmab A/S (GE9)

Open: 77.480 Day's Range: 77.140 - 77.600 Volume: 0
Previous Close: 77.470 52wk Range: 26.880 - 79.930 1-Yr Rtn: +180.45%

Stock Chart for GE9

No chart data available.
  • GE9:GR 77.600
  • 1D
  • 1M
  • 1Y
77.470
Interactive GE9 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GE9

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 102.5734
Relative P/E vs. DAX -
Earnings Per Share (DKK) (ttm) -
Est. EPS (DKK) (12/2015) 5.6410
Est. PEG Ratio 2.1334
Market Cap (M EUR) 4,556.48
Shares Outstanding (M) 58.72
30 Day Average Volume 244
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/11/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GE9

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GE9

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GE9

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil